

Adaptive Therapeutic Systems: Integrating Real-Time Biosensing, AI and Personalized Medicine

Danielle Li

Professor MIT Sloan School of Management

Abstract

The convergence of real-time biosensing, artificial intelligence (AI), wearable technologies, digital health platforms, and precision medicine is creating a new generation of adaptive therapeutic systems capable of continuously responding to individual patient conditions. Conventional therapeutic models generally rely on periodic clinical assessments and predefined treatment protocols, which may not adequately capture rapid changes in physiological status, treatment response, or disease progression. Adaptive therapeutic systems seek to address this limitation by creating continuous feedback loops between biosensing, data analytics, clinical decision-making, and therapeutic intervention. This paper examines the emerging architecture of adaptive therapeutic systems and evaluates the integration of real-time biosensing technologies with AI and personalized medicine. It explores applications in chronic disease management, cardiovascular monitoring, diabetes, neurological disorders, oncology, rehabilitation, and medication optimisation. Particular attention is given to wearable and implantable sensors, physiological signal processing, machine learning, digital biomarkers, predictive modelling, closed-loop treatment systems, and patient-specific therapeutic adjustment. The paper proposes an Adaptive Therapeutic Intelligence Framework consisting of five interconnected layers: biosensing and data acquisition, physiological data integration, AI-based interpretation, personalised decision support, and adaptive intervention. The study also discusses challenges related to sensor reliability, data interoperability, algorithmic bias, explainability, cybersecurity, patient privacy, clinical validation, regulatory oversight, and human-AI collaboration. It argues that the future of personalised medicine will increasingly move from static treatment plans toward continuously learning therapeutic systems that adapt to changing biological conditions. However, such systems must remain clinically validated, transparent, secure, and human-centred. The paper concludes that the integration of real-time biosensing and AI provides a foundation for more responsive, predictive, and personalised healthcare, particularly when technological innovation is combined with rigorous clinical evidence and responsible governance.

Keywords: Adaptive Therapeutic Systems, Real-Time Biosensing, Artificial Intelligence, Personalized Medicine, Digital Biomarkers, Wearable Sensors, Precision Medicine, Machine Learning, Closed-Loop Therapy, Digital Health.

1. Introduction

Healthcare has traditionally followed a relatively periodic model:

Patient Visit → Clinical Assessment → Diagnosis → Treatment → Follow-Up

Although this approach remains essential, many diseases involve physiological changes that occur between clinical appointments.

For example, a patient's:

- Heart rate,
- glucose level,
- blood pressure,
- oxygen saturation,
- sleep pattern,
- physical activity,
- neurological activity,

may change substantially over time.

Real-time biosensing technologies provide an opportunity to continuously observe these changes.

When such information is combined with AI and personalised medicine, healthcare can potentially move toward:


Sense → Interpret → Predict → Adapt → Monitor


This represents the fundamental concept of an adaptive therapeutic system.

2. Concept of Adaptive Therapeutic Systems

An adaptive therapeutic system is a healthcare system capable of modifying therapeutic recommendations or interventions in response to continuously changing patient information.

The basic architecture is:





The feedback loop allows treatment strategies to evolve with the patient's condition.

3. From Personalized Medicine to Adaptive Medicine

Personalized medicine generally aims to select treatment according to individual characteristics.

Adaptive medicine extends this concept.

Instead of asking:

Which treatment is appropriate for this patient?

the system can additionally ask:

How should treatment change as this patient's condition changes?

This creates a transition from:

Static Personalisation → Dynamic Personalisation

4. Real-Time Biosensing

Biosensing technologies can collect information continuously or at frequent intervals.

Examples include:

- Wearable heart-rate sensors.
- Continuous glucose monitors.
- Pulse oximeters.
- Blood-pressure devices.
- Temperature sensors.
- Electrocardiography systems.
- Electroencephalography systems.
- Implantable sensors.

5. Wearable Biosensors

Wearable devices can collect physiological and behavioural information during everyday activities.

Potential measurements include:

- Heart rate.
- Heart-rate variability.
- Physical activity.
- Sleep.

- Respiratory rate.
- Skin temperature.
- Electrodermal activity.

This information can create longitudinal patient profiles.

6. Continuous Glucose Monitoring

Continuous glucose monitoring is an important example of real-time biosensing.

Instead of relying exclusively on occasional glucose measurements, continuous systems provide repeated measurements throughout the day.

AI can analyse glucose patterns alongside:

- Food intake.
- Exercise.
- Medication.
- Sleep.
- Stress.

This can support more individualised diabetes management.

7. Cardiovascular Monitoring

Wearable and remote monitoring systems can analyse:

- Heart rate.
- ECG signals.
- Heart-rate variability.
- Activity.
- Blood pressure.

AI algorithms can identify patterns that may warrant clinical attention.

8. Remote Patient Monitoring

Remote monitoring extends healthcare beyond hospitals and clinics.

A typical system involves:

Patient → Sensor → Mobile Device → Cloud Platform → AI → Clinician

This can be particularly useful for long-term disease management.

9. Digital Biomarkers

Digital biomarkers are measurable physiological or behavioural characteristics collected through digital technologies.

Examples include:

- Activity patterns.
- Sleep characteristics.
- Heart-rate variability.
- Movement characteristics.

- Speech features.

They can provide additional information about disease progression and treatment response.

10. AI-Based Physiological Signal Processing

Physiological signals can contain:

- Noise.
- Missing data.
- Motion artefacts.
- Individual variability.

AI and signal-processing techniques can help identify meaningful patterns.

The process can be represented as:

Raw Signal → Noise Reduction → Feature Extraction → AI Classification → Clinical Interpretation

11. Machine Learning for Personalized Prediction

Machine-learning models can identify relationships between:

- Patient characteristics.
- Physiological measurements.
- Treatment history.
- Clinical outcomes.

The objective is not simply to classify patients but to predict how an individual patient may respond under different conditions.

12. Patient Digital Profiles

An adaptive therapeutic system can create a continuously updated patient profile containing:

- Demographic information.
- Medical history.
- Laboratory measurements.
- Medication information.
- Sensor data.
- Treatment response.
- Behavioural patterns.

This can support longitudinal personalisation.

13. Digital Twins in Healthcare

A healthcare digital twin can represent selected aspects of an individual's physiological or clinical state.

Potential applications include:

- Treatment simulation.
- Risk prediction.

- Disease progression modelling.
- Therapy optimisation.

Digital twins remain an emerging area and require substantial validation before routine clinical use.

14. Predictive Therapeutics

Traditional clinical care often responds to symptoms after they emerge.

Predictive therapeutic systems attempt to identify early signals.

The progression can be:

Detection → Prediction → Prevention → Intervention

This can potentially reduce adverse events and unnecessary interventions.

15. Adaptive Drug Therapy

AI-supported systems could help clinicians evaluate treatment response using:

- Physiological measurements.
- Laboratory results.
- Medication history.
- Patient-reported outcomes.

Treatment recommendations can then be reassessed as new evidence becomes available.

16. Closed-Loop Therapeutic Systems

A closed-loop system continuously connects sensing with intervention.

The conceptual structure is:

Measure → Analyse → Decide → Intervene → Measure Again

Examples include certain automated insulin-delivery systems and other emerging therapeutic technologies.

17. Diabetes Management

Diabetes is particularly suited to adaptive therapeutic approaches because glucose levels change continuously.

Potential inputs include:

- Glucose.
- Meals.
- Exercise.
- Medication.
- Activity.
- Sleep.

AI can identify individual patterns and support dynamic treatment decisions.

18. Cardiovascular Disease

Adaptive systems can support cardiovascular management through continuous monitoring.

Potential applications include:

- Arrhythmia detection.
- Blood-pressure management.
- Heart-failure monitoring.
- Post-discharge surveillance.

19. Neurological Disorders

Wearable and neurological sensors can provide information about:

- Movement.
- Tremor.
- Gait.
- Sleep.
- Seizure-related activity.

AI can analyse longitudinal patterns to support personalised monitoring.

20. Parkinson's Disease

Movement sensors can measure:

- Tremor.
- Bradykinesia.
- Gait.
- Activity.

Such measurements may provide additional information about disease fluctuations and therapeutic response.

21. Epilepsy Monitoring

Continuous or long-duration physiological monitoring can potentially identify patterns associated with seizure risk.

AI can assist in analysing complex neurological signals.

However, clinical validation and false-alarm management are critical.

22. Oncology

Personalised cancer treatment increasingly incorporates:

- Genomic information.
- Tumour characteristics.
- Treatment response.
- Patient-specific clinical data.

AI can potentially integrate these data sources to support adaptive treatment planning.

23. Precision Oncology

An adaptive oncology system could combine:

Genomics + Imaging + Laboratory Data + Treatment Response + Patient Monitoring
to support continuous reassessment of therapeutic strategies.

24. Rehabilitation

Wearable sensors can monitor:

- Movement.
- Muscle activity.
- Range of motion.
- Exercise performance.

AI can adjust rehabilitation recommendations according to patient progress.

25. AI-Powered Physical Rehabilitation

A rehabilitation system could:

1. Measure movement.
2. Identify abnormalities.
3. Compare performance with previous sessions.
4. Predict recovery trends.
5. Adjust exercise recommendations.

This creates a personalised rehabilitation feedback loop.

26. Mental and Behavioural Health

Digital signals may provide information about:

- Sleep.
- Activity.
- Communication patterns.
- Behavioural changes.

AI could potentially identify changes requiring clinical attention, although ethical and privacy safeguards are especially important.

27. Multimodal Patient Data

Adaptive systems become more powerful when multiple data streams are integrated.

For example:


Wearable Data

•

Electronic Health Records

•

Laboratory Results



28. Patient-Specific Models

Population-level models may not capture every individual's biological characteristics. Adaptive systems can use personalised models that learn from the patient's own historical data.

This can potentially improve:

- Prediction.
- Risk estimation.
- Treatment personalisation.

29. Reinforcement Learning

Reinforcement learning provides a conceptual framework for adaptive decision-making. The system can evaluate:

Patient State → Action → Response → Reward/Outcome

and learn which actions are associated with better outcomes.

However, clinical reinforcement learning requires particularly strong safety constraints.

30. Explainable AI

Healthcare decisions require transparency.

Clinicians should understand:

- Why a model generated a prediction.
- Which factors influenced the result.
- How confident the system is.
- What alternative interpretations exist.

Explainability is therefore essential for clinical adoption.

31. Human-AI Collaboration

Adaptive therapeutic systems should generally support rather than replace clinical expertise.

A practical architecture is:

AI Recommendation → Clinician Review → Patient-Centred Decision

This maintains human oversight.

32. Patient-Centred Adaptation

Patients should participate in therapeutic decisions.

Systems should consider:

- Patient preferences.
- Lifestyle.
- Treatment burden.
- Accessibility.
- Goals.

Personalisation should therefore include both biological and behavioural dimensions.

33. Real-Time Clinical Decision Support

AI systems can provide alerts concerning:

- Abnormal physiological trends.
- Potential deterioration.
- Treatment response.
- Medication-related concerns.

Alert systems must be carefully designed to avoid excessive notifications.

34. Alert Fatigue

Too many alerts can overwhelm clinicians and patients.

AI systems should therefore prioritise alerts according to:

- Severity.
- Probability.
- Clinical relevance.
- Urgency.

35. Data Interoperability

Adaptive therapeutic systems depend on integration across:

- Wearables.
- Hospitals.
- Laboratories.
- Pharmacies.
- Electronic health records.

Interoperability remains a major technical challenge.

36. Edge Computing

Some health data can be processed locally on devices rather than being transmitted continuously to cloud platforms.

Advantages may include:

- Lower latency.
- Reduced bandwidth requirements.
- Improved privacy.
- Greater system resilience.

37. Federated Learning

Federated learning can allow models to learn across distributed datasets without requiring all patient data to be centrally collected.

Potential benefits include:

- Improved privacy.
- Distributed learning.
- Institutional collaboration.

However, federated systems still require strong security and governance.

38. Privacy and Security

Adaptive systems handle highly sensitive information.

Potential risks include:

- Unauthorised access.
- Data breaches.
- Re-identification.
- Model attacks.
- Insecure devices.

Security must therefore be integrated from system design onward.

39. Algorithmic Bias

AI systems can perform differently across patient populations when training data are not sufficiently representative.

Potential sources of bias include:

- Demographic imbalance.
- Limited geographic representation.
- Unequal access to digital devices.
- Incomplete clinical datasets.

40. Clinical Validation

A technically accurate model is not automatically a clinically useful system.

Validation should examine:

- Diagnostic performance.
- Treatment outcomes.
- Safety.
- Robustness.
- Generalisability.

Prospective clinical evaluation is particularly important for adaptive interventions.

41. Regulatory Considerations

Adaptive medical technologies may involve complex regulatory questions because algorithms can change or update over time.

Regulatory frameworks therefore need to address:

- Software updates.
- Model monitoring.
- Clinical evidence.
- Cybersecurity.
- Accountability.

42. Accountability

When an AI-supported therapeutic recommendation contributes to an adverse outcome, responsibility must be clearly defined.

Potential stakeholders include:

- Technology developers.
- Healthcare providers.
- Institutions.
- Clinicians.
- Device manufacturers.

Clear accountability frameworks are essential.

43. Patient Consent

Patients should understand:

- What data are collected.
- Why they are collected.
- How AI uses them.
- Who can access them.
- How long data are retained.

Meaningful consent should be an ongoing process where appropriate.

44. Energy and Environmental Considerations

Large-scale AI healthcare infrastructure requires:

- Computing.

- Data storage.
- Network infrastructure.

Sustainable healthcare AI should therefore consider the environmental footprint of computational systems.

45. Proposed Adaptive Therapeutic Intelligence Framework

The proposed framework consists of five layers.

Layer 1 — Real-Time Biosensing

Wearables, implantables, medical devices and laboratory measurements.

Layer 2 — Data Integration

Electronic health records, sensor data and patient-reported information.

Layer 3 — AI Intelligence

Prediction, classification, anomaly detection and personalised modelling.


Layer 4 — Therapeutic Decision Support

Treatment recommendations and risk prioritisation.

Layer 5 — Adaptive Intervention

Therapeutic adjustment followed by continuous monitoring.

46. Conceptual Model



Continuous Biosensing

The closed feedback loop is the defining feature of adaptive therapeutic systems.

47. Adaptive Therapeutic Maturity Model

Level	Capability
Level 1	Periodic clinical monitoring
Level 2	Digital remote monitoring
Level 3	Predictive clinical analytics
Level 4	Personalised therapeutic recommendations
Level 5	Clinically supervised adaptive therapy

48. Key Performance Indicators

KPI	Purpose
Prediction accuracy	Model performance
False-alert rate	Safety and usability
Treatment response	Therapeutic effectiveness
Patient adherence	Engagement
Time-to-intervention	Responsiveness
Hospitalisation rate	Clinical outcome
Sensor reliability	Data quality
Model drift	Long-term performance
Privacy incidents	Security
Patient satisfaction	User experience

49. Implementation Roadmap

Phase 1 — Data Foundation

Establish reliable biosensing and clinical data infrastructure.

Phase 2 — Monitoring

Implement continuous patient monitoring.

Phase 3 — Prediction

Develop validated AI prediction models.

Phase 4 — Decision Support

Integrate AI into clinical workflows.

Phase 5 — Adaptive Intervention

Enable carefully controlled therapeutic adjustment.

Phase 6 — Continuous Evaluation

Monitor clinical outcomes, safety and algorithmic performance.

50. Major Challenges

The development of adaptive therapeutic systems faces several challenges:

1. Sensor reliability.
2. Data interoperability.
3. Patient privacy.
4. Cybersecurity.
5. Algorithmic bias.
6. Model explainability.
7. Clinical validation.
8. Regulatory uncertainty.
9. Alert fatigue.
10. Clinician acceptance.
11. Patient engagement.
12. Long-term model drift.

51. Future Research Directions

Future research should examine:

- Multimodal biosensing.
- AI-driven closed-loop therapies.
- Personalised digital twins.
- Federated healthcare AI.
- Adaptive drug-delivery systems.
- Digital biomarkers.
- AI-guided rehabilitation.
- Real-time oncology monitoring.
- Neuroadaptive therapeutic systems.
- Privacy-preserving personalised medicine.

52. Discussion

Adaptive therapeutic systems represent a fundamental shift in healthcare architecture.

Traditional medicine often treats the patient based on information available at a specific clinical moment.

Adaptive systems attempt to understand the patient as a continuously changing biological system.

This distinction is important.

A patient's physiological state can change because of:

- Medication.
- Diet.
- Exercise.
- Sleep.
- Stress.
- Disease progression.
- Environmental conditions.

Continuous biosensing provides visibility into these changes, while AI can convert large volumes of data into interpretable predictions.

The most important innovation is therefore not simply the sensor or the AI model.

It is the feedback loop connecting sensing, intelligence and therapeutic action.

53. Strategic Implications

Healthcare organisations seeking to implement adaptive therapeutic technologies should develop integrated capabilities across:

Clinical Science + Data Engineering + AI + Biosensing + Cybersecurity + Patient Engagement

Successful implementation requires interdisciplinary collaboration.

54. Recommendations

Healthcare organisations should:

1. Establish interoperable health-data infrastructures.
2. Validate biosensing technologies before clinical deployment.
3. Use AI primarily as clinically supervised decision support.
4. Develop patient-specific models where clinically justified.
5. Implement continuous model monitoring.
6. Establish strong privacy and cybersecurity controls.
7. Evaluate algorithmic bias across patient populations.
8. Minimise unnecessary alerts.
9. Involve patients in system design.
10. Conduct prospective clinical evaluations of adaptive interventions.

55. Conclusion

Adaptive therapeutic systems represent an emerging convergence of real-time biosensing, artificial intelligence and personalised medicine.

The central transformation is:

Periodic Monitoring → Continuous Sensing → Predictive Intelligence → Adaptive Intervention

Real-time biosensors can provide continuous information about physiological and behavioural states.

AI can transform these data into predictions, identify deviations from individual baselines, and support personalised clinical decisions.

When integrated into carefully validated feedback loops, these capabilities can contribute to more responsive management of chronic diseases, cardiovascular conditions, diabetes, neurological disorders, rehabilitation and other areas of healthcare.

However, adaptive healthcare cannot be built solely through technological innovation.

Reliable sensors, high-quality data, explainable AI, clinical validation, cybersecurity, privacy protection, regulatory oversight and human clinical judgement are equally important.

The future of personalised medicine is therefore likely to move beyond selecting the right treatment for the right patient toward continuously adapting treatment to the changing needs of the individual.

The overarching model can be expressed as:

Real-Time Biosensing + AI + Personalised Medicine + Clinical Oversight = Adaptive Therapeutic Intelligence

Such systems have the potential to make healthcare more predictive, responsive and individualised while maintaining the safety and human-centred principles required for responsible clinical practice.

References

1. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25, 44–56.
2. Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine*, 380(14), 1347–1358.
3. Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25, 24–29.
4. Goldberger, A. L., Amaral, L. A. N., Glass, L., et al. (2000). PhysioBank, PhysioToolkit, and PhysioNet. *Circulation*, 101(23), e215–e220.
5. Dunn, J., Runge, R., & Snyder, M. (2018). Wearables and the medical revolution. *Personalized Medicine*, 15(5), 429–448.
6. Coravos, A., Goldsack, J. C., Karlin, D. R., et al. (2019). Digital biomarkers to accelerate drug development. *Nature Reviews Drug Discovery*, 18, 599–601.

7. Steinhubl, S. R., Muse, E. D., & Topol, E. J. (2015). The emerging field of mobile health. *Science Translational Medicine*, 7(283), 283rv3.
8. Rumsfeld, J. S., Joynt, K. E., & Maddox, T. M. (2016). Big data analytics to improve cardiovascular care. *Journal of the American College of Cardiology*, 68(9), 930–941.
9. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA*, 319(13), 1317–1318.
10. Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: Review, opportunities and challenges. *Briefings in Bioinformatics*, 19(6), 1236–1246.
11. Krittanawong, C., Johnson, K. W., Rosenson, R. S., et al. (2020). Deep learning for cardiovascular medicine. *Nature Reviews Cardiology*, 17, 653–664.
12. Gambus, P. L., & O'Connor, M. F. (2018). Artificial intelligence and machine learning in anaesthesia and intensive care. *British Journal of Anaesthesia*, 120(4), 847–848.
13. Chen, M., Hao, Y., Hwang, K., Wang, L., & Wang, L. (2017). Disease prediction by machine learning over big data from healthcare communities. *IEEE Access*, 5, 8869–8879.
14. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA*, 319(13), 1317–1318.
15. Sendak, M. P., D'Arcy, J., Kashyap, S., et al. (2020). A path for translation of machine learning products into healthcare delivery. *EMJ Innovations*, 2020, 56–63.